| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006188318 |
| P356 | DOI | 10.2165/00002512-200421080-00003 |
| P698 | PubMed publication ID | 15182216 |
| P2093 | author name string | Mark R Burge | |
| Aruna Chelliah | |||
| P2860 | cites work | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian Study of Health and Aging | Q34034652 | ||
| Hypoglycemia. Pathophysiology and treatment | Q34125384 | ||
| Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis | Q34221721 | ||
| The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor | Q34502378 | ||
| Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms | Q34563673 | ||
| Role of hepatic autoregulation in defense against hypoglycemia in humans | Q34627940 | ||
| Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas | Q34741360 | ||
| Hypoglycemia in diabetes. | Q35135643 | ||
| Diabetes in institutionalised elderly people: a forgotten population? | Q36245154 | ||
| Adrenergic Mechanisms for the Effects of Epinephrine on Glucose Production and Clearance in Man | Q37021401 | ||
| Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia | Q37039189 | ||
| Effects of Glycemic Control on Protective Responses Against Hypoglycemia in Type 2 Diabetes | Q57420307 | ||
| Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes | Q57420344 | ||
| Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients | Q67831458 | ||
| Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control | Q68123283 | ||
| Attenuated glucose recovery from hypoglycemia in the elderly | Q68127285 | ||
| Hypoglycemia in hospitalized patients. Causes and outcomes | Q68912475 | ||
| Hypoglycemia: still a risk in the elderly | Q68931755 | ||
| Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents | Q69579956 | ||
| Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion | Q69861247 | ||
| The role of autoregulation of the hepatic glucose production in man. Response to a physiologic decrement in plasma glucose | Q69875742 | ||
| Severe hypoglycemia in diabetic patients: frequency, causes, prevention | Q69892179 | ||
| Dose-response characteristics for effects of insulin on production and utilization of glucose in man | Q70157794 | ||
| Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial | Q70881052 | ||
| Altered responses to hypoglycemia of healthy elderly people | Q72501754 | ||
| Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release | Q72554912 | ||
| Hypoglycemia unawareness in IDDM | Q72612230 | ||
| Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes | Q72787250 | ||
| Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM | Q72800093 | ||
| Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia | Q72874429 | ||
| Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group | Q77223580 | ||
| Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication | Q77634855 | ||
| Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses | Q37370189 | ||
| Drug-induced hypoglycemia. A review of 1418 cases. | Q38602971 | ||
| Oral hypoglycemic agents | Q38700011 | ||
| The impact of aging on adrenergic receptor function: clinical and biochemical aspects | Q39347627 | ||
| Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. | Q39777241 | ||
| Metformin and the sulphonylureas: the comparative risk | Q39850311 | ||
| Brain metabolism: a perspective from the blood-brain barrier | Q40167105 | ||
| Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. | Q40335783 | ||
| Glucose counterregulation: prevention and correction of hypoglycemia in humans | Q40883259 | ||
| Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans | Q41156510 | ||
| Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia | Q41179920 | ||
| Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization | Q41206360 | ||
| Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man | Q41533316 | ||
| Sulfonylureas | Q41603300 | ||
| Cognitive function during hypoglycaemia in type I diabetes mellitus. | Q41949820 | ||
| Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas | Q42051043 | ||
| Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas | Q42055798 | ||
| Incidence of severe sideeffects during therapy with sulfonylureas and biguanides. | Q42224709 | ||
| Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden | Q42249106 | ||
| Managing diabetes in residential and nursing homes | Q43150177 | ||
| Incidence and costs of severe hypoglycemia | Q43409590 | ||
| Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction | Q43510788 | ||
| Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects | Q43565623 | ||
| Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). | Q43584175 | ||
| Oxidative fuel metabolism during mild hypoglycemia: critical role of free fatty acids | Q43715351 | ||
| Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemic symptoms | Q43794605 | ||
| Hypoglycemia-associated autonomic failure in advanced type 2 diabetes | Q43901612 | ||
| Association of health literacy with diabetes outcomes | Q44073610 | ||
| Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes | Q44114813 | ||
| Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia | Q44126989 | ||
| Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia | Q44243542 | ||
| Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial | Q44479625 | ||
| Putting diabetes to the test: Analyzing glycemic control based on patients' diabetes knowledge | Q44495300 | ||
| Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population | Q46547840 | ||
| Diabetes-related morbidity and mortality in a national sample of U.S. elders | Q48619194 | ||
| Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme | Q49194198 | ||
| Rates of hypoglycemia in users of sulfonylureas. | Q50623917 | ||
| Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care. | Q50888487 | ||
| Individual sulfonylureas and serious hypoglycemia in older people. | Q51027313 | ||
| Undiagnosed NIDDM: clinical and public health issues. | Q51059960 | ||
| Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. | Q51554477 | ||
| Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. | Q51555685 | ||
| Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. | Q51559563 | ||
| A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. | Q51572019 | ||
| Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. | Q51575321 | ||
| Benefits and Risks With Glyburide and Glipizide in Elderly NIDDM Patients | Q51607251 | ||
| Studies on posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus. | Q51627534 | ||
| Differential effects of epinephrine on glucose production and disposal in man | Q51661488 | ||
| Influences of age and exercise on glucose metabolism: implications for management of older diabetics. | Q54206175 | ||
| Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. | Q54340182 | ||
| Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). | Q54465258 | ||
| Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. | Q55062500 | ||
| P433 | issue | 8 | |
| P921 | main subject | hypoglycemia | Q202758 |
| prevention | Q1717246 | ||
| P1104 | number of pages | 20 | |
| P304 | page(s) | 511-530 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention | |
| P478 | volume | 21 |
| Q34563587 | Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options |
| Q42171306 | Approach to managing hypoglycemia in elderly patients with diabetes |
| Q51362596 | Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. |
| Q37688018 | Development of CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project: rationale and methodology. |
| Q38281522 | Diabetes in older people: new insights and remaining challenges. |
| Q33903514 | Diabetes in the elderly |
| Q37992956 | Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? |
| Q40084842 | Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes? |
| Q37799813 | Drug-induced hypoglycaemia: an update |
| Q64116572 | Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study |
| Q38410465 | Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial |
| Q42694248 | Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes |
| Q51693237 | Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis. |
| Q33636971 | Efficacy of treatment for hyperglycemic crisis in elderly diabetic patients in a day hospital. |
| Q37969988 | European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary |
| Q37468480 | Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment |
| Q30438098 | Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes |
| Q46721352 | Fluoroquinolone-associated dysglycemias: a tale of two toxicities |
| Q92326973 | Frequency and Predisposing Factors for Drug-Induced Hypoglycemia in Patients with Type-2 Diabetes Mellitus |
| Q38663548 | Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM). |
| Q37020450 | Hypoglycaemia in residential care homes |
| Q35195244 | Hypoglycemia in older people - a less well recognized risk factor for frailty |
| Q41791225 | Hypoglycemia is independently associated with multidimensional impairment in elderly diabetic patients |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q37858364 | Incretin therapies in the management of elderly patients with type 2 diabetes mellitus |
| Q44086731 | Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. |
| Q37017362 | Insulin use in elderly diabetic patients |
| Q35073384 | Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines |
| Q37468429 | Management of type 2 diabetes mellitus in older patients: current and emerging treatment options |
| Q33577712 | Optimal therapy of type 2 diabetes: a controversial challenge |
| Q36430326 | Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia |
| Q27025548 | Patient safety and minimizing risk with insulin administration - role of insulin degludec |
| Q40757441 | Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment |
| Q35841565 | Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study |
| Q60923410 | Recent clinical trials in diabetes – implications for managing older patients |
| Q38162813 | Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project |
| Q83343521 | Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients |
| Q33781944 | Risk factors for recurrent hypoglycemia in hospitalized diabetic patients admitted for severe hypoglycemia. |
| Q34591309 | Severe hypoglycemia from clarithromycin-repaglinide drug interaction |
| Q37858366 | Special considerations for the use of insulin in older adults |
| Q57052731 | Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study |
| Q48194144 | The GesTIO protocol experience: safety of a standardized order set for subcutaneous insulin regimen in elderly hospitalized patients |
| Q38152414 | The older patient with diabetes: a practical approach |
| Q44753592 | Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes |
| Q38000974 | Treatment of type 2 diabetes in the elderly |
| Q35681641 | Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study |
| Q39145953 | Uncertainties around incretin-based therapies: A literature review |
| Q37058172 | Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. |
Search more.